ERIVEDGE
150mgERIVEDGE150mg
ERIVEDGE (Vismodegib) 150mg is a first-in-class Hedgehog pathway inhibitor (SMO inhibitor) by Roche for the treatment of advanced basal cell carcinoma (BCC).
Key Benefits
- First-in-class Hedgehog pathway inhibitor approved for advanced BCC
- Oral once-daily dosing — convenient 150mg capsule
- Clinically proven efficacy in both metastatic and locally advanced BCC
- No cold chain required — room temperature storage
- Over 10 years of clinical experience since FDA approval in 2012
- Addresses critical unmet need for patients with inoperable BCC
Contact Us for Pricing
Get competitive wholesale pricing for ERIVEDGE 150mg. Our team is available 24/7.
Direct line: +44 7429 917553
Licensed Supplier
Authorized pharmaceutical distributor
100% Original
Guaranteed authentic products
Worldwide Delivery
International shipping available
24/7 Support
WhatsApp support anytime
How ERIVEDGE Works
Vismodegib is a small molecule that selectively binds to and inhibits Smoothened (SMO), a transmembrane protein essential for Hedgehog (Hh) pathway signal transduction. In normal tissue, the Hh pathway is largely inactive in adults. However, in >90% of BCCs, loss-of-function mutations in PTCH1 or gain-of-function mutations in SMO cause constitutive pathway activation, driving tumor cell proliferation and survival. By inhibiting SMO, vismodegib blocks downstream transcription factor GLI activation, resulting in growth arrest and apoptosis of BCC tumor cells.
About ERIVEDGE 150mg
ERIVEDGE (Vismodegib) 150mg hard capsules by Roche/Genentech is the world's first FDA-approved systemic therapy for advanced basal cell carcinoma (BCC). Approved in January 2012, Erivedge revolutionized the treatment of patients with metastatic BCC (mBCC) or locally advanced BCC (laBCC) who are not candidates for surgery or radiation. Vismodegib works by selectively inhibiting Smoothened (SMO), a transmembrane protein in the Hedgehog (Hh) signaling pathway. In over 90% of BCCs, this pathway is constitutively activated due to mutations in PTCH1 or SMO genes, driving uncontrolled tumor proliferation. By blocking SMO, vismodegib shuts down this aberrant signaling, inducing tumor regression and shrinkage. In the pivotal ERIVANCE BCC trial, Erivedge demonstrated an overall response rate of 30.3% in metastatic BCC and 42.9% in locally advanced BCC, with many patients achieving significant tumor reduction or complete responses. The drug is taken as a convenient once-daily oral capsule. As a licensed pharmaceutical supplier based in Turkey, we provide authentic Roche Erivedge with competitive wholesale pricing for hospitals, oncology clinics, dermatology centers, and pharmaceutical distributors worldwide. Erivedge is an oral medication stored at room temperature — no cold chain required. Contact us via WhatsApp for current pricing and availability.
Common Uses
- Metastatic basal cell carcinoma (mBCC)
- Locally advanced basal cell carcinoma (laBCC) — recurrent after surgery
- Advanced BCC in patients not candidates for surgery or radiation
- Hedgehog pathway-driven cancers
Dosage Information
150mg orally once daily, with or without food. Swallow capsule whole — do not open, crush, or chew. No dose adjustment needed for renal or hepatic impairment. Continue treatment until disease progression, unacceptable toxicity, or patient decision. Each box contains 28 hard capsules (one month's supply).
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store below 30°C (86°F). No refrigeration required. Store in original packaging to protect from moisture. Keep out of reach of children. Shelf life: 36 months from manufacture date.
We ensure proper cold chain handling during shipping to maintain product integrity.
Frequently Asked Questions About ERIVEDGE
Find answers to common questions about ordering, pricing, and shipping.
Related Oncology Medications Products
Explore more oncology medications medications from our catalog
